Poly(3-hexylthiophene) as a versatile semiconducting polymer for cutting-edge bioelectronics
Abdel Aziz I., Tullii G., Antognazza MR., Criado-Gonzalez M.
Narrative Review, published in Mater Horiz (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Mater Horiz (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40331312
- PMCID
- PMC12056706
- DOI
- 10.1039/d5mh00096c
- Citations
- 3
Abstract (original English)
Semiconducting polymers (SPs), widely used in organic optoelectronics, are gaining interest in bioelectronics owing to their intrinsic optical properties, conductivity, biocompatibility, flexibility, and chemical tunability. Among them, poly(3-hexylthiophene) (P3HT) has attracted great attention as a versatile SP, being both optically active and conductive, for the fabrication of smart materials ( e.g. , films and nanoparticles), allowing the modulation of their performance and final biomedical applications. This review article provides an overview of the design of different kinds of P3HT-based materials, from chemical properties to structural engineering, to be used as key opto-electronic components in the development of opto-transducers for the modulation of cell fate, as well as biosensors such as organic electrochemical transistors (OECTs) and organic field effect transistors (OEFTs). Finally, their foremost applications in the biomedical field ranging from tissue engineering to biosensing will be discussed, including the future perspectives of P3HT derivatives towards cutting-edge applications for bioelectronics, in which optoceutics plays a key role.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.